Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Rituximab is frequently used for post-transplant lymphoproliferative disorder (PTLD) after hematopoietic cell transplantation (HCT).
• The assumption of negligible rituximab toxicity (infections due to hypogammaglobulinemia and neutropenia) in HCT patients requires further investigation.

Purpose of the Study:

• To evaluate the impact of rituximab on immunoglobulin levels, neutrophil counts, infection rates, and mortality in HCT recipients.
• To determine if the benefits of rituximab for PTLD outweigh its potential risks.

Main Methods:

• Retrospective analysis of 349 HCT recipients.
• Comparison between 60 patients receiving rituximab (preemptively or therapeutically) and 289 patients not receiving rituximab.
• Assessment of immunoglobulin levels (IgM, IgG, IgA), neutrophil counts, infection density, and mortality outcomes up to 24 months post-transplantation.

Main Results:

• Rituximab recipients showed significantly lower IgM, IgG, and IgA levels at 6 and 12 months post-HCT.
• Higher incidence of severe neutropenia and increased non-Epstein-Barr viral infection density observed in the rituximab group.
• The rituximab group experienced a higher incidence of fatal infections, nonrelapse mortality, and overall mortality compared to the no-rituximab group.

Conclusions:

• Rituximab administration for PTLD in HCT recipients is associated with significant morbidity and mortality.
• The study findings challenge the assumption of negligible toxicity and suggest a need for careful risk-benefit assessment.
• Further research is needed to determine if the benefits of preemptive rituximab outweigh its associated risks.